ChemAxon Announces New CEO and Head of R&D
BUDAPEST, Hungary, May 12 — ChemAxon, a software
solutions provider for cheminformatics, today announced the appointment of
Alex Drijver as CEO. The arrival signals the companies increased focus on
business development and market position. Ferenc Csizmadia, founder and
former CEO, moves to Chairman and Head of Research and Development. The new
R&D position formalises the bridge between the customer base and the
company’s development strategy and in particular the next generation of
products under launch.
Alex joins ChemAxon with over 20 years international commercial
experience, most recently as CEO and CFO of ThalesNano Inc, a Budapest
based manufacturer of novel microfluidic based instruments for chemical
synthesis, and CFO of ComGenex, Inc., a chemistry services provider now
part of Albany Molecular.
ChemAxon is a leader in providing cheminformatics software development
platforms and applications for the biotechnology, pharmaceutical and
agrochemical industries. With core capabilities for structure
visualization, search and management, property prediction, virtual
synthesis, screening and drug design, ChemAxon focuses upon active
interaction with users and software portability to create powerful, cost
effective cross platform solutions and programming interfaces to power
modern cheminformatics and chemical communication. For more information
please visit http://www.chemaxon.com.